In conjunction with a healthy diet, metabolic optimization through the use of 5-Amino-1MQ could contribute to increased longevity, decreased weight gain, and improved overall health
It also supports disease resistance contributing to antibody production and the elimination of pathogens
Micronutrient supplementation interventions in preconception and pregnant women at increased risk of developing pre-eclampsia: a systematic review and meta-analysis
When Does Hair Loss Begin
Directions for Future Research: Investigations should focus on confirming the efficacy of tirzepatide in type 1 diabetes, elucidating the neuroprotective potential of GLP-1/GIP dual agonists, optimizing perioperative protocols, and facilitating the clinical translation of novel multi-receptor agonists
(2023), New England Journal of Medicine 389(6), DOI 10.1056/NEJMoa2301972 Statistics from clinical literature Developer: Eli Lilly and Company , code name LY3437943 Mechanism: triple agonist acting at GLP-1 , GIP and glucagon receptors, the first such peptide in advanced clinical development Phase 2 obesity trial (NEJM 2023) results at 12 mg/week dose, n=338: 24.2 % mean reduction in body weight at 48 weeks 25.8 % loss of body fat (DEXA) 9.7 % reduction in hemoglobin A1c in prediabetic patients Phase 2 type 2 diabetes trial (Lancet 2023): 2.02 % point A1c reduction at 36 weeks vs
